Iradimed Corp (IRMD) · Oct 30, 2026 · Earnings

Iradimed earnings beat revenue, but 2026 guidance slips

In line — Non-GAAP EPS $0.55 vs ~$0.55 consensus; revenue $24.2M vs ~$23.47M; FY revenue midpoint cut to $92.35M from $93.5M

Iradimed earnings beat revenue expectations as its 3870 pump gains traction, but lower full-year guidance keeps the quarter mixed.

Iradimed is in the commercial ramp of its next-generation 3870 MRI-compatible infusion pump, with 2026 expected to be the transition year from launch to broader distribution; earlier production inefficiencies were a known pressure point.

The quarter cleared the revenue bar, but not by enough to make the whole update a clean beat. Revenue reached $24.2 million, up 14% year over year and about 3% above the published consensus of roughly $23.47 million, while non-GAAP diluted EPS of $0.55 matched the approximately $0.55 consensus. The operating result was therefore better than expected on sales, but essentially in line on adjusted earnings.

Q3 2026Q3 2025Consensus / prior guide
Revenue (Financial Highlights)$24.2M (+14%)$21.2M~$23.47M consensus
GAAP diluted EPS (Income Statement)$0.51 (+19%)$0.43
Non-GAAP diluted EPS (Non-GAAP reconciliation)$0.55 (+17%)$0.47~$0.55 consensus
Gross margin (Financial Highlights)76%78%
FY2026 revenue guidance (Outlook)$91.6M–$93.1M$91.0M–$96.0M prior guide
FY2026 non-GAAP EPS guidance (Outlook)$2.07–$2.11$2.06–$2.21 prior guide

The strategic signal is stronger than the headline earnings result. Management says bookings reached records, monitor-unit bookings set another record, domestic pump-channel bookings rose 45% year over year, and more than 70% of pump bookings used the four-pump “quad stack” configuration. That points to customers replacing older systems and adopting the 3870 platform, not merely a one-quarter shipment spike. 〔0〕

The main offset is that management lowered the full-year range despite the stronger quarter. The revenue midpoint fell from $93.5 million to $92.35 million, while the non-GAAP EPS midpoint declined from $2.135 to $2.09. That suggests the 3870 ramp is progressing, but the company is still allowing for execution or timing friction as production scales. The gross margin also remained below last year’s level at 76%, although management said sequential improvement began as manufacturing efficiencies emerged. 〔1〕

The balance sheet gives the ramp room to continue without outside financing. Cash increased to $63.3 million from $51.2 million at year-end, and nine-month free cash flow reached $20.1 million versus $11.0 million a year earlier (Balance Sheet; Free Cash Flow reconciliation). The new quarterly dividend remains modest relative to that cash generation and does not change the central story: execution of the 3870 rollout is still the key variable.

Bottom line: This was a revenue beat and a credible 3870 demand update, but adjusted earnings merely matched expectations and management trimmed the full-year outlook. The business story is advancing, though the ramp is not yet translating into a clean upward reset of expectations.

Original filing on SEC EDGAR

Iradimed earnings beat revenue, but 2026 guidance slips | IRMD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.